Why AZ Respiratory Head Believes Third-Placed Benralizumab Can Conquer Market
Executive Summary
AstraZeneca hopes its investigative biologic benralizumab has strongly differentiated itself from rival therapies Nucala and Cinqair with the detailed publication of Phase III data showing it significantly cut exacerbations and improved lung function and symptoms in patients with severe eosinophilic asthma, as well as offering a favorable dosing schedule.
You may also be interested in...
AstraZeneca’s Benralizumab Asthma Chase Gets Underway
Watch out GlaxoSmithKline and Teva: AstraZeneca's benralizumab has wind in its sails following a EU CHMP positive opinion for severe asthma. Approval in the US is also expected by year end.
Keeping Track: A Blizzard Of Submissions And A Small Flurry Of Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
GSK's Nucala Shows Promise In A Rare Systemic Vasculitis
GlaxoSmithKline is cementing its leadership position in eosinophilic conditions with promising pivotal results with Nucala as an add-on therapy for the rare disorder eosinophilic granulomatosis with polyangiitis. The development is expected to lead to an extension of its indications.